News | July 15, 2009

Philips Acquires Therapeutic Hypothermia Company InnerCool Therapies

InnerCool's Accutrol catheter for endovascular cooling and warming of patients.

July 15, 2009 – Royal Philips said today it reached an agreement to acquire the assets of InnerCool Therapies Inc., a pioneer in the field of therapeutic hypothermia.

InnerCool, a wholly-owned subsidiary of Cardium Therapeutics Inc., will be acquired in an asset purchase transaction for $11.25 million as well as the transfer of approximately $1.5 million in trade payables. Philips said the transaction will reinforce the company’s leadership position in the emergency care market by adding body temperature management solutions to its existing product offering in this field.

The new product line will enable Philips to broaden its offerings in emergency care, and to eventually expand to future applications for acute myocardial infarction and stroke to help preserve heart and brain tissue.

Therapeutic hypothermia solutions aim to safely induce, maintain and reverse hypothermia or maintain normal body temperature, to preserve organs such as the heart and brain in the event of sudden cardiac arrest (SCA). This rapidly-advancing technology has been recognized by the American Heart Association and the International Liaison Committee on Resuscitation as crucial in improving the survival and neurological recovery for SCA patients.

InnerCool Therapies will position Philips for continued growth in the cardiology care cycle by enhancing its industry-leading emergency care solutions offered globally. Today this includes comprehensive patient monitoring, clinical decision support tools, defibrillation therapy, CPR measurement and feedback and medical consumables. Philips expects to see continued growth in emergency care as medical systems and hospitals invest in innovative technologies that can significantly impact the outcome for patients who experience life-threatening emergencies.

With this acquisition, Philips becomes the only company that offers a comprehensive suite of both surface (external) and endovascular (internal) body temperature management solutions in a market currently experiencing double digit growth. More than 10 years of extensive research and development by InnerCool will also provide Philips with a rich patent portfolio and pipeline of future products, Philips said.

For more information: www.philips.com, www.innercool.com

Related Content

therapeutic hypothermia, children, cardiac arrest, treatment, temperature
Feature | May 04, 2015
A large-scale, multicenter study has shown that therapeutic hypothermia does not improve survival rates or reduce brain...
News | December 11, 2014
Researchers at Okayama University in collaboration with several medical centers in Japan have demonstrated the safety...
Feature | September 19, 2014
September 19, 2014 — According to a new study, peritoneal hypothermia is feasible for patients who have suffered ST-...
Technology | July 10, 2014
July 10, 2014 — Life Recovery Systems announced the U.S. Food and Drug Administration (FDA) has approved two...
therapeutic hypothermia, Philips InnerCool

The Philips InnerCool RTx system was used in the CHILL-MI study for use in STEMI patients.

Feature | February 03, 2014 | Dave Fornell
Use of therapeutic hypothermia is used to prevent neurological damage in patients who suffer sudden cardiac arrest (SCA...
BeneChill RhinoChill Therapeutic Hypothermia Cath Lab Intranasal Cooling System
News | January 22, 2014
BeneChill Inc. received the 2014 Frost & Sullivan Award for Technology Innovation Leadership for its RhinoChill...
rhinochill, RhinoChill, benechill, BeneChill

RhinoChill IntraNasal Cooling System

News | December 03, 2013
With the benefits of conventional strategies for therapeutic hypothermia following cardiac arrest being called in to ...
therapeutic hypothermia temperature management cath lab clinical trial study
Feature | November 01, 2013
clinical trial shows that rapidly cooling...
News | October 01, 2013
The Cardiovascular Research Foundation (CRF) announced the late breaking trials and first report investigations that...
News | August 06, 2013
Vanderbilt Heart and Vascular Institute is participating in the VELOCITY study, a randomized controlled clinical study...
Overlay Init